Molecular Remission Following High-Dose Hydroxyurea and Fludarabine Plus Cytarabine in a Patient with Simultaneous Acute Myeloid Leukemia and Low-Grade Lymphoma

E. Montefusco Department of Cellular Biotechnology and Hematology, University “La Sapienza”, Rome, ItalyCorrespondence[email protected]

F. Fazi Department of Cellular Biotechnology and Hematology, University “La Sapienza”, Rome, Italy

I. Cordone Department of Cellular Biotechnology and Hematology, University “La Sapienza”, Rome, Italy

C. Ariola Department of Cellular Biotechnology and Hematology, University “La Sapienza”, Rome, Italy

M. Nanni Department of Cellular Biotechnology and Hematology, University “La Sapienza”, Rome, Italy

A. Spadea Department of Cellular Biotechnology and Hematology, University “La Sapienza”, Rome, Italy

M. A. Aloe Spiriti Department of Cellular Biotechnology and Hematology, University “La Sapienza”, Rome, Italy

S. Fenu Department of Cellular Biotechnology and Hematology, University “La Sapienza”, Rome, Italy

F. Mandelli Department of Cellular Biotechnology and Hematology, University “La Sapienza”, Rome, Italy

M. C. Petti Department of Cellular Biotechnology and Hematology, University “La Sapienza”, Rome, Italy

show all

Abstract

The occurrence of acute myeloid leukemia (AML) as a secondary tumor has been frequently reported in patients who received various chemotherapy regimens for hematologic malignancies wile the concomitant development of chronic lymphoproliferative diseases (CLD) and AML in previously untreated patients is extremely rare. We report a case with an apparently spontaneous occurrence of AML and non Hodgkin low-grade lymphoma diagnosed by immunological, cytogenetical and molecular analyses. In particular genetic studies allowed to identify the coexistence of a clonal lymphoid population and a myeloid blast component characterized by inv(16) marker and CBFbeta-MYH11 gene fusion. Complete remission of AML and the CLD was obtained following high doses of hydroxyurea and two consolidation cycles of fludarabine plus intermediate dose cytarabine.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Molecular Remission Following High-Dose Hydroxyurea and Fludarabine Plus Cytarabine in a Patient with Simultaneous Acute Myeloid Leukemia and Low-Grade Lymphoma

Information for

Open access

Opportunities

Help and information

Molecular Remission Following High-Dose Hydroxyurea and Fludarabine Plus Cytarabine in a Patient with Simultaneous Acute Myeloid Leukemia and Low-Grade Lymphoma

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature